The stock of Inotek Pharmaceuticals Corp (NASDAQ:ITEK) is a huge mover today! About 182,846 shares traded hands. Inotek Pharmaceuticals Corp (NASDAQ:ITEK) has risen 24.79% since March 10, 2016 and is uptrending. It has outperformed by 17.28% the S&P500.
The move comes after 8 months positive chart setup for the $199.32M company. It was reported on Oct, 13 by Barchart.com. We have $17.99 PT which if reached, will make NASDAQ:ITEK worth $259.12M more.
Analysts await Inotek Pharmaceuticals Corp (NASDAQ:ITEK) to report earnings on November, 10. They expect $-0.44 EPS, down 76.00% or $0.19 from last year’s $-0.25 per share. After $-0.33 actual EPS reported by Inotek Pharmaceuticals Corp for the previous quarter, Wall Street now forecasts 33.33% negative EPS growth.
Inotek Pharmaceuticals Corp (NASDAQ:ITEK) Ratings Coverage
Out of 4 analysts covering Inotek Pharmaceuticals Corporation (NASDAQ:ITEK), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Inotek Pharmaceuticals Corporation has been the topic of 4 analyst reports since July 27, 2015 according to StockzIntelligence Inc. Chardan Capital Markets initiated Inotek Pharmaceuticals Corp (NASDAQ:ITEK) on Wednesday, December 2 with “Buy” rating. The rating was maintained by Piper Jaffray with “Overweight” on Tuesday, July 28. The stock has “Buy” rating given by H.C. Wainwright on Tuesday, September 20.
According to Zacks Investment Research, “Inotek Pharmaceuticals Corporation is a biopharmaceutical company. The company is focused on the discovery, development and commercialization of novel therapies to treat glaucoma and diseases of the eye. Inotek Pharmaceuticals Corporation is headquartered in Lexington, Massachusetts.”
More notable recent Inotek Pharmaceuticals Corp (NASDAQ:ITEK) news were published by: Businesswire.com which released: “Inotek Pharmaceuticals to Present at the 2016 Ophthalmology Innovation Summit” on April 21, 2016, also Fool.com with their article: “Why Inotek Pharmaceuticals Corporation Stock Rose 28.4% in April” published on May 10, 2016, Businesswire.com published: “Inotek Pharmaceuticals Corporation Reports Second Quarter 2016 Financial …” on August 10, 2016. More interesting news about Inotek Pharmaceuticals Corp (NASDAQ:ITEK) were released by: Quotes.Wsj.com and their article: “News Inotek Pharmaceuticals Corp.ITEK” published on January 31, 2015 as well as Businesswire.com‘s news article titled: “Inotek Pharmaceuticals Appoints Carsten Boess to Board of Directors” with publication date: January 12, 2016.
ITEK Company Profile
Inotek Pharmaceuticals Corporation, incorporated on July 7, 1999, is a clinical-stage biopharmaceutical company. The Firm is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The Company’s lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye’s natural pressure control mechanism. The Firm developed this molecule to selectively stimulate a particular adenosine subreceptor in the eye with the effect of augmenting the intrinsic function of the eye’s trabecular meshwork (TM).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.